Efficacy of interferon alpha for the treatment of hospitalized patients with COVID-19: A meta-analysis.
COVID-19
IFN-α
SARS-CoV-2
interferon-α
mortality
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
14
10
2022
accepted:
12
01
2023
entrez:
13
2
2023
pubmed:
14
2
2023
medline:
15
2
2023
Statut:
epublish
Résumé
IFN-α intervention may block SARS-CoV-2 replication and normalize the deregulated innate immunity of COVID-19. This meta-analysis aimed to investigate the efficacy of interferon IFN-α-containing regimens when treating patients with moderate-to-severe COVID-19. PubMed, SCOPUS, and ClinicalTrials.gov were searched from inception to 15 January 2022. A systematic literature search was conducted by applying relevant terms for 'COVID-19' and 'interferon-α'. The primary outcome enclosed the all-cause hospital mortality. The secondary outcomes constituted the length of hospital stay; hospital discharge; nucleic acid negative conversion. Eleven studies are enclosed in the meta-analysis. No significant difference in the all-cause mortality rate was found between the study and control groups (OR 0.2; 95% CI 0.05-1.2; I Thus, IFN-α does not benefit the survival of hospitalized COVID-19 patients but may increase the number of patients discharged from the hospital. www.crd.york.ac.uk/prospero, identifier (CRD42022374589).
Identifiants
pubmed: 36776844
doi: 10.3389/fimmu.2023.1069894
pmc: PMC9909279
doi:
Substances chimiques
Antiviral Agents
0
Interferon-alpha
0
Types de publication
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1069894Informations de copyright
Copyright © 2023 Buchynskyi, Kamyshna, Lyubomirskaya, Moshynets, Kobyliak, Oksenych and Kamyshnyi.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Virol. 2020 Nov 9;94(23):
pubmed: 32938761
Int J Infect Dis. 2021 Apr;105:516-521
pubmed: 33713817
Clin Drug Investig. 2021 Dec;41(12):1037-1046
pubmed: 34687413
EClinicalMedicine. 2021 Feb;32:100743
pubmed: 33615206
J Interferon Cytokine Res. 2020 Dec;40(12):543-548
pubmed: 33337934
Biomed Pharmacother. 2021 Dec;144:112230
pubmed: 34628168
Sci Rep. 2021 Apr 13;11(1):8059
pubmed: 33850184
Cell Host Microbe. 2020 Sep 9;28(3):455-464.e2
pubmed: 32707096
J Interferon Cytokine Res. 2020 Dec;40(12):578-588
pubmed: 33337933
Annu Rev Virol. 2019 Sep 29;6(1):567-584
pubmed: 31283436
J Clin Epidemiol. 2021 Jun;134:103-112
pubmed: 33577987
Cell. 2020 May 28;181(5):1036-1045.e9
pubmed: 32416070
J Interferon Cytokine Res. 2021 Jun;41(6):205-219
pubmed: 34161170
J Interferon Cytokine Res. 2020 Sep;40(9):438-442
pubmed: 32960147
J Med Virol. 2021 Sep;93(9):5277-5284
pubmed: 34101851
Clin Cardiol. 2020 Dec;43(12):1624-1630
pubmed: 33094522
Viruses. 2021 Dec 11;13(12):
pubmed: 34960758
Antiviral Res. 2020 Jul;179:104811
pubmed: 32360182
Cell Rep. 2022 Jun 14;39(11):110954
pubmed: 35671758
Virol Sin. 2022 Apr;37(2):295-298
pubmed: 35597770
J Crit Care. 2020 Dec;60:32-37
pubmed: 32736197
J Zhejiang Univ Sci B. 2020 Aug.;21(8):628-636
pubmed: 32748578
Ann Med. 2022 Dec;54(1):516-523
pubmed: 35118917
Cytokine Growth Factor Rev. 2022 Feb;63:34-43
pubmed: 35115233
Viruses. 2021 Mar 29;13(4):
pubmed: 33805458
Viruses. 2022 Feb 25;14(3):
pubmed: 35336884
Cell Host Microbe. 2020 Jun 10;27(6):870-878
pubmed: 32464097
Eur J Pharmacol. 2022 Jul 15;927:175051
pubmed: 35618037
J Mol Biol. 2022 Mar 30;434(6):167265
pubmed: 34562466
J Infect Chemother. 2021 Jun;27(6):876-881
pubmed: 33676844
Expert Rev Anti Infect Ther. 2022 May;20(5):741-747
pubmed: 34747295
Lancet. 2022 May 21;399(10339):1941-1953
pubmed: 35512728
Br J Clin Pharmacol. 2021 Dec;87(12):4737-4746
pubmed: 33982806
Int J Infect Dis. 2021 Mar;104:641-648
pubmed: 33515771